EP1256340A1 — Improved transdermal therapeutic system for the treatment of Parkinson's disease
Assigned to UCB Pharma GmbH · Expires 2002-11-13 · 24y expired
What this patent protects
This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm 2 and containing 0.1 to 3.15 mg / cm 2 of Rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which effects an improvement, compared…
USPTO Abstract
This invention provides the use of a silicone-based transdermal therapeutic system having an area of 10 to 40 cm 2 and containing 0.1 to 3.15 mg / cm 2 of Rotigotine as active ingredient, for the preparation of an anti-Parkinson medicament which effects an improvement, compared to a placebo treatment, of the condition of human Parkinson patients, measured according to the Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III, of 2 units or more following administration for a time period of at least 7 weeks.
Drugs covered by this patent
- Neupro (ROTIGOTINE) · UCB
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.